Plain-English translation of NCT07168772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether Lactibane Iki, a probiotic supplement, can help people with relapsing-remitting multiple sclerosis when added to their current MS medications. Half of the 80 participants will receive the actual probiotic twice a day for six months, while the other half will receive a placebo (a lookalike with no active ingredient). Researchers want to see if this medication helps with MS symptoms or disease progression.
Recent research suggests that gut bacteria may play a role in how the immune system behaves in multiple sclerosis. This trial exists to find out whether taking this medication could improve outcomes for people already on standard MS treatments by potentially supporting a healthier gut environment.
You likely qualify if…
You likely don't qualify if…
You would take either the probiotic or a placebo as a powder sachet mixed with water twice each day for six months. You would continue taking your regular MS medications as you normally do. The study team will monitor you throughout to track any effects on your MS symptoms and overall health. You'll need to commit to taking the supplement consistently and reporting back to the research team during the six-month period.
AI-generated summary from trial data · Aug 16, 2026 · Not medical advice
Spain